^
Association details:
| Biomarker: | SPOP mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) + abiraterone acetate (CYP17A1 inhibitor) + Erleada (apalutamide) (Androgen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1373P - SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)
Published date:
09/05/2022
Excerpt:
37 pts (8.7%) were mtSPOP(+). Results are summarized in the table. Pts with mtSPOP receiving ARAT had improved median TTCR and OS compared to wild-type SPOP (wtSPOP)….In this real-world analysis, mtSPOP was associated with improved outcomes with ADT+ARAT (but not ADT+docetaxel) in dn-mCSPC pts. Based on these results, SPOP status may represent a predictive biomarker guiding treatment selection in dn-mCSPC.
